2023 - Research.com Medicine in Netherlands Leader Award
Jacques J.M. van Dongen mainly investigates Immunology, Molecular biology, Gene rearrangement, B cell and Minimal residual disease. His is doing research in Antigen, Antibody, CD19, Immunophenotyping and Immune system, both of which are found in Immunology. His Molecular biology research incorporates themes from Dendritic cell, Recombination-activating gene, RAG2 and Gene, Severe combined immunodeficiency.
The various areas that he examines in his Gene rearrangement study include Cellular differentiation, T cell, T-cell receptor, Regulation of gene expression and Polymerase chain reaction. His B cell research is multidisciplinary, incorporating elements of DNA and Immunoglobulin heavy chain. His study in Minimal residual disease is interdisciplinary in nature, drawing from both Flow cytometry, Acute lymphocytic leukemia and Oncology.
Immunology, Molecular biology, Antibody, Internal medicine and Immunophenotyping are his primary areas of study. His work in B cell, Bone marrow, Immune system, EuroFlow and Antigen are all subfields of Immunology research. In his study, Polymerase chain reaction is inextricably linked to Gene rearrangement, which falls within the broad field of Molecular biology.
Jacques J.M. van Dongen has researched Internal medicine in several fields, including Surgery and Oncology. In Immunophenotyping, he works on issues like Leukemia, which are connected to Cancer research. The study incorporates disciplines such as Acute lymphocytic leukemia and Transplantation in addition to Minimal residual disease.
His scientific interests lie mostly in Immunophenotyping, Immunology, Flow cytometry, EuroFlow and Antibody. His research integrates issues of Cancer research, Leukemia and Bone marrow in his study of Immunophenotyping. His Flow cytometry research is multidisciplinary, relying on both Myeloid, Pathology, Lymphocyte, Tissue damage and Multiple myeloma.
His research in EuroFlow intersects with topics in Orientation, Newborn screening and Acute leukemia. Jacques J.M. van Dongen specializes in Antibody, namely B cell. His B cell research integrates issues from Second line treatment, Chronic lymphocytic leukemia, Melphalan and Minimal residual disease.
The scientist’s investigation covers issues in Internal medicine, Oncology, Minimal residual disease, EuroFlow and Flow cytometry. His Internal medicine study integrates concerns from other disciplines, such as Text mining and Fusion gene. His studies in Oncology integrate themes in fields like Survival rate, Clinical endpoint, Randomized controlled trial and Surrogate endpoint.
His Minimal residual disease research is multidisciplinary, incorporating perspectives in Progression-free survival, Chemoimmunotherapy, Primer, Computational biology and DNA sequencing. His work in Flow cytometry addresses subjects such as Cancer research, which are connected to disciplines such as Immunophenotyping. Jacques J.M. van Dongen integrates Viral pathogenesis with Immunology in his research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.
J J M van Dongen;A W Langerak;M Brüggemann;P A S Evans.
Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program
J Gabert;E Beillard;V H J van der Velden;W Bi.
Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program
E Beillard;N Pallisgaard;V H J van der Velden;W Bi.
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
Jacques Jm van Dongen;Taku Seriu;E Renate Panzer-Grümayer;Andrea Biondi.
The Lancet (1998)
Immunophenotyping of blood lymphocytes in childhood: Reference values for lymphocyte subpopulations
W.Marieke Comans-Bitter;Ronald de Groot;René van den Beemd;Herman J. Neijens.
The Journal of Pediatrics (1997)
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.
J J M van Dongen;L Lhermitte;S Böttcher;J Almeida.
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study
Valentino Conter;Claus R. Bartram;Maria Grazia Valsecchi;Andre Schrauder.
Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.
V H J van der Velden;A Hochhaus;G Cazzaniga;T Szczepanski.
Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.
V H J van der Velden;G Cazzaniga;A Schrauder;J Hancock.
EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols
T Kalina;J Flores-Montero;V H J van der Velden;M Martin-Ayuso.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: